Written by students who passed Immediately available after payment Read online or as PDF Wrong document? Swap it for free 4.6 TrustPilot
logo-home
Document preview thumbnail
Preview 4 out of 45 pages
Exam (elaborations)

WGU D027 Advanced Pathopharmacological Foundations Final Exam – Comprehensive OA Practice 2026/2027 Edition

Document preview thumbnail
Preview 4 out of 45 pages

This document provides a comprehensive practice resource for the WGU D027 Advanced Pathopharmacological Foundations final assessment, designed to help students review advanced concepts in disease processes and pharmacologic management. It covers essential topics including cellular injury, inflammation, immune responses, cardiovascular and respiratory disorders, endocrine and renal conditions, neurological disorders, and pharmacological principles. The practice material is designed to reinforce pathopharmacology concepts, support self-assessment, and improve overall assessment readiness.

Content preview

WGU D027 ADVANCED
PATHOPHARMACOLOGICAL FOUNDATIONS FINAL
EXAM

COMPREHENSIVE OA PRACTICE (2026/2027 EDITION)




200 Multiple-Choice Questions - Complete OA Practice




Independent-Study Disclaimer
This practice examination is an independent study aid and is not affiliated with, endorsed by, or sponsored by
Western Governors University (WGU) or any other institution. It is provided for educational and self-assessment
purposes only and is not a substitute for official WGU D027 course materials, assessments, or professional
guidance. Standards and evidence are subject to change; always consult current course materials, guidelines,
and clinical references.

, Section 1: Cellular & Genetic Foundations – Adaptation, Injury, Genetics,
Neoplasia, Fluid/Electrolytes (30 questions)
Q1: Which type of cellular adaptation involves a decrease in cell size?
A. Hypertrophy
B. Hyperplasia
C. Metaplasia
D. Atrophy [CORRECT]
Correct Answer: D
Rationale: Atrophy is a decrease in cell size. Hypertrophy increases size, hyperplasia increases number,
and metaplasia is a change in cell type.

Q2: Which type of cellular adaptation involves an increase in cell size?
A. Atrophy
B. Metaplasia
C. Hypertrophy [CORRECT]
D. Dysplasia
Correct Answer: C
Rationale: Hypertrophy is an increase in cell size. Atrophy decreases size, and the others differ.

Q3: Which type of cellular adaptation involves an increase in the number of cells?
A. Hyperplasia [CORRECT]
B. Hypertrophy
C. Atrophy
D. Metaplasia
Correct Answer: A
Rationale: Hyperplasia is an increase in cell number. The others are different adaptations.

Q4: Which type of cellular adaptation is a reversible change in which one adult cell type is replaced by another?
A. Dysplasia
B. Metaplasia [CORRECT]
C. Atrophy
D. Hyperplasia
Correct Answer: B
Rationale: Metaplasia is the replacement of one adult cell type by another. Dysplasia is disordered growth,
and the others differ.

Q5: Which of the following is a disorderly, often pre-neoplastic cell growth?
A. Metaplasia
B. Dysplasia [CORRECT]
C. Hyperplasia
D. Atrophy
Correct Answer: B
Rationale: Dysplasia is disordered growth, often pre-neoplastic. The others are different adaptations.



WGU D027 Advanced Pathopharmacological Foundations - 2026/2027 Edition Page 2

, Q6: Which type of necrosis is most typical of ischemic cell death (e.g., in a myocardial infarction)?
A. Liquefactive necrosis
B. Coagulative necrosis [CORRECT]
C. Caseous necrosis
D. Fat necrosis
Correct Answer: B
Rationale: Coagulative necrosis is typical of ischemia (e.g., MI). Liquefactive occurs in the brain, caseous in
TB, and fat necrosis in fatty tissue.

Q7: Which type of necrosis is characteristic of a tuberculous infection?
A. Coagulative necrosis
B. Caseous necrosis [CORRECT]
C. Liquefactive necrosis
D. Fat necrosis
Correct Answer: B
Rationale: Caseous necrosis is characteristic of TB. The others are different types of necrosis.

Q8: Which type of necrosis is most typical of the brain?
A. Coagulative necrosis
B. Caseous necrosis
C. Fibrinoid necrosis
D. Liquefactive necrosis [CORRECT]
Correct Answer: D
Rationale: The brain undergoes liquefactive necrosis. Coagulative is typical of other organs. The others
differ.

Q9: Which of the following is programmed cell death that is energy-dependent and does not typically trigger
inflammation?
A. Necrosis
B. Gangrene
C. Caseation
D. Apoptosis [CORRECT]
Correct Answer: D
Rationale: Apoptosis is programmed, energy-dependent cell death without inflammation. Necrosis triggers
inflammation. The others differ.

Q10: Which of the following is TRUE about necrosis?
A. It is programmed cell death
B. It is unregulated cell death that triggers an inflammatory response [CORRECT]
C. It is always benign
D. It does not cause inflammation
Correct Answer: B
Rationale: Necrosis is unregulated cell death with inflammation. Apoptosis is programmed. The others are
incorrect.




WGU D027 Advanced Pathopharmacological Foundations - 2026/2027 Edition Page 3

, Q11: Which of the following is the hallmark of acute inflammation?
A. Neutrophil infiltration and edema [CORRECT]
B. Lymphocyte infiltration and fibrosis
C. Granuloma formation
D. Scar tissue
Correct Answer: A
Rationale: Acute inflammation features neutrophils and edema. Chronic inflammation features lymphocytes,
granulomas, and fibrosis.

Q12: Which of the following is a mediator of the immune response?
A. Cytokines, interleukins, and chemokines [CORRECT]
B. Only glucose
C. Only electrolytes
D. Only oxygen
Correct Answer: A
Rationale: Cytokines, interleukins, and chemokines are immune mediators. The others are not.

Q13: Which of the following is TRUE about the role of genetics in disease?
A. Genetics has no role
B. All diseases are purely genetic
C. Genetic variations can influence disease risk and drug metabolism (pharmacogenomics) [CORRECT]
D. Genetics only affects appearance
Correct Answer: C
Rationale: Genetic variations influence disease risk and drug metabolism. The others are incorrect.

Q14: Which of the following is an example of pharmacogenomics?
A. Giving the same dose to everyone
B. Ignoring genetics
C. Using CYP2D6 genotype to guide drug selection/dosing [CORRECT]
D. Using age alone for dosing
Correct Answer: C
Rationale: Pharmacogenomics uses genetic variants (e.g., CYP2D6) to guide therapy. The others are
incorrect.

Q15: Which enzyme is commonly involved in pharmacogenomic drug metabolism?
A. CYP2D6 (and other CYP enzymes) [CORRECT]
B. Amylase
C. Trypsin
D. Pepsin
Correct Answer: A
Rationale: CYP enzymes, especially CYP2D6, are key in drug metabolism. The others are digestive
enzymes.




WGU D027 Advanced Pathopharmacological Foundations - 2026/2027 Edition Page 4

Document information

Uploaded on
August 17, 2026
Number of pages
45
Written in
2026/2027
Type
Exam (elaborations)
Contains
Questions & answers
$14.49

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Sold
3
Followers
0
Items
140
Last sold
6 hours ago


Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions